You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 47 No. 5, May 1990 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL CONTRIBUTIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (89)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Frontal Lobe Function in Progressive Supranuclear Palsy

Jordan Grafman, PhD; Irene Litvan, MD; Claudia Gomez, MA; Thomas N. Chase, MD

Arch Neurol. 1990;47(5):553-558.


Abstract



• Performance on tasks evaluating "executive and attentional" processes presumably subserved by prefrontal cortex were compared in patients with progressive supranuclear palsy and with age- and education-matched control subjects. The results indicated that patients with progressive supranuclear palsy were particularly impaired when a task required sequential movements, conceptual shifting, monitoring the frequency with which stimuli are presented, or rapid retrieval of verbal knowledge. These deficits could not simply be accounted for by slowed information processing or by a deficit in representational knowledge. Conceivably, "weak activation" of frontal lobe representational knowledge characterized by an observed attentional deficit results in the neuropsychological impairments noted in patients with progressive supranuclear palsy. The oral administration of physostigmine, under double-blind placebo-controlled conditions, did not facilitate executive or attentional performance as evaluated by our tasks.



Author Affiliations



From the Cognitive Neuroscience Unit, Medical Neurology Branch (Dr Grafman) and Experimental Therapeutics Branch (Drs Litvan and Chase and Ms Gomez), National Institute of Neurological Disorders and Stroke, Bethesda, Md.


Footnotes



Accepted for publication September 29, 1989.

The opinions and assertions contained herein are the private views of the authors, and are not to be construed as official or necessarily reflecting the views of the National Institutes of Health, the United States Public Health Service, the Department of Health and Human Services, or the Uniformed Services University of the Health Sciences.

Reprint requests to the Cognitive Neuroscience Unit, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bldg 10, Room 5C422, Bethesda, MD 20892 (Dr Grafman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chapter 40 Movement disorders
Fletcher
Brain's Diseases of the Nervous System 2009;12:med-9780198569381-chapter-med-9780198569381-chapter.
ABSTRACT | FULL TEXT  

Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy
Brenneis et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:246-249.
ABSTRACT | FULL TEXT  

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan et al.
Neurology 2001;57:467-473.
ABSTRACT | FULL TEXT  

Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy
Soliveri et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:313-318.
ABSTRACT | FULL TEXT  

Progressive supranuclear palsy
Rehman
Postgrad. Med. J. 2000;76:333-336.
ABSTRACT | FULL TEXT  

PET measures of benzodiazepine receptors in progressive supranuclear palsy
Foster et al.
Neurology 2000;54:1768-1773.
ABSTRACT | FULL TEXT  

Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy
Kertzman et al.
Arch Neurol 1990;47:1346-1350.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.